

## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Ayvakit Prior Authorization Policy

- Ayvakit™ (avapritinib tablets – Blueprint Medicines)

**REVIEW DATE:** 07/13/2022

---

### OVERVIEW

Ayvakit, a kinase inhibitor, is indicated in adults for the following uses:<sup>1</sup>

- **Gastrointestinal stromal tumor (GIST)**, unresectable or metastatic, harboring a platelet-derived growth factor receptor alpha (*PDGFRA*) exon 18 mutation, including *PDGFRA* D842V mutations. Patients should be selected for treatment with Ayvakit based on the presence of a *PDGFRA* exon 18 mutation; an FDA-approved test for the detection of this mutation is not currently available.
- **Systemic mastocytosis**, advanced, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia. Ayvakit is not recommended for the treatment of patients with advanced systemic mastocytosis with platelet counts of less than  $50 \times 10^9/L$ .

### Guidelines

Ayvakit is discussed in the guidelines from National Comprehensive Cancer Network (NCCN):<sup>3</sup>

- **GIST:** NCCN guidelines (version 1.2022 – January 21, 2022), note that Ayvakit is one of the primary treatment options for GIST with *PDGFRA* exon 18 mutation, including *PDGFRA* D842V mutations (category 2A).<sup>2</sup> Imatinib is a category 1 recommended option for primary treatment. The guidelines note that most mutations in the *PDGFRA* gene are associated with a response to imatinib, with the notable exception of *PDGFRA* D842V mutation. Ayvakit (for *PDGFRA* exon 18 mutation that is insensitive to imatinib, including the *D842V* mutation) is listed as a preferred regimen for neoadjuvant therapy for resectable GISTs with significant morbidity (category 2A). Ayvakit is listed as an additional option after failure on approved therapies. The approved therapies are imatinib and Ayvakit® (avapritinib tablets; for *PDGFRA* mutation) as first-line therapy; Sutent® (sunitinib capsules) or Sprycel® (dasatinib tablets; for *PDGFRA* exon 18 mutations that are insensitive to imatinib [including the *PDGFRA* *D842V* mutation) as second-line therapy; Stivarga® (regorafenib tablets) as third-line therapy; and Qinlock® (ripretinib tablets) as fourth-line therapy.
- **Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes:** NCCN guidelines (version 1.2022 – April 14, 2022) note that since Ayvakit targets *PDGFRA* exon 18 mutation, it may have a role for use in patients with *FIP1L1-PDGFRA* positive myeloid/lymphoid neoplasms with eosinophilia harboring *PDGFRA* D842V mutation, which is resistant to imatinib (category 2A).<sup>4</sup> If this mutation is identified a clinical trial of Ayvakit is preferred (if available), rather than off-label use.
- **Systemic Mastocytosis:** NCCN guidelines (version 1.2022 – April 14, 2022) recommend single-agent Ayvakit if the patient has platelets  $\geq 50 \times 10^9/L$  as preferred treatment of aggressive systemic mastocytosis, systemic mastocytosis with an associated neoplasm, and mast cell leukemia with or without an associated hematologic neoplasm (category 2A).<sup>5</sup>

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Ayvakit. All approvals are provided for the duration noted below.

07/13/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Ayvakit is recommended in those who meet one of the following criteria:

#### FDA-Approved Indications

1. **Gastrointestinal Stromal Tumor.** Approve for 1 year if the patient meets the following criteria (A and B):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) Patient meets ONE of the following criteria (i or ii):
    - i. The tumor is positive for platelet-derived growth factor receptor alpha (*PDGFRA*) exon 18 mutation; OR  
*Note:* *PDGFRA* exon 18 mutation includes *PDGFRA* D842V mutations.
    - ii. Patient has tried each of the following (a, b, c, and d):
      - a) Imatinib; AND
      - b) One of Sutent (sunitinib capsules) or Sprycel (dasatinib tablets); AND
      - c) Stivarga (regorafenib tablets); AND
      - d) Qinlock (ripretinib tablets).
2. **Systemic Mastocytosis.** Approve for 1 year if the patient meets the following criteria (A, B, and C):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) Patient has a platelet count  $\geq 50 \times 10^9/L$  ( $\geq 50,000/mcL$ ); AND
  - C) Patient has one of the following subtypes of advanced systemic mastocytosis (i, ii, or iii):
    - i. Aggressive systemic mastocytosis; OR
    - ii. Systemic mastocytosis with an associated hematological neoplasm; OR
    - iii. Mast cell leukemia.

#### Other Uses with Supportive Evidence

3. **Myeloid/Lymphoid Neoplasms.** Approve for 1 year if the patient meets the following criteria (A, B, and C):
  - A) Patient is  $\geq 18$  years of age; AND
  - B) Patient has eosinophilia; AND
  - C) The tumor is positive for platelet-derived growth factor receptor alpha (*PDGFRA*) D842V mutation.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Ayvakit is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Ayvakit™ tablets [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; June 2021.
2. The NCCN Gastrointestinal Stromal Tumors Clinical Practice Guidelines in Oncology (version 1.2022 – January 21, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 7, 2022.
3. The NCCN Drugs & Biologics Compendium. © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 7, 2022. Search term: avapritinib.

4. The NCCN Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes Clinical Practice Guidelines in Oncology (version 1.2022 – April 14, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 7, 2022.
5. The NCCN Systemic Mastocytosis Clinical Practice Guidelines in Oncology (version 1.2022 – April 14, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 7, 2022.